KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 105 filers reported holding KEROS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $114,925,104 | -29.5% | 3,604,928 | -11.2% | 0.01% | -28.6% |
| Q2 2023 | $163,092,266 | -52.9% | 4,059,041 | -49.9% | 0.01% | -12.5% |
| Q1 2023 | $346,029,954 | +95.9% | 8,103,746 | +120.3% | 0.02% | -11.1% |
| Q4 2022 | $176,669,854 | +21.6% | 3,679,089 | -4.8% | 0.02% | +20.0% |
| Q3 2022 | $145,346,000 | +46.1% | 3,863,526 | +7.3% | 0.02% | +50.0% |
| Q2 2022 | $99,465,000 | -39.2% | 3,599,895 | +19.7% | 0.01% | -23.1% |
| Q1 2022 | $163,571,000 | -20.2% | 3,007,936 | -14.2% | 0.01% | -13.3% |
| Q4 2021 | $205,066,000 | +48.1% | 3,504,798 | +0.1% | 0.02% | +36.4% |
| Q3 2021 | $138,487,000 | -6.7% | 3,500,679 | +0.2% | 0.01% | -8.3% |
| Q2 2021 | $148,413,000 | -17.7% | 3,494,539 | +19.3% | 0.01% | -20.0% |
| Q1 2021 | $180,226,000 | -3.4% | 2,928,117 | +10.7% | 0.02% | -11.8% |
| Q4 2020 | $186,551,000 | +170.4% | 2,644,620 | +47.9% | 0.02% | +142.9% |
| Q3 2020 | $68,984,000 | +35.3% | 1,788,545 | +31.5% | 0.01% | +16.7% |
| Q2 2020 | $51,001,000 | – | 1,359,672 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |